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Overweight and obese not only increase the risk of cardiovascular disease and type-2 2 
diabetes mellitus, but are also now known risk factors for a variety of cancers . Weight 3 
control, via dietary calorie restriction (DCR) and/or exercise, has been demonstrated to 4 
be beneficial for cancer prevention in various experimental models, but the underlying 5 
mechanisms are still not well defined. Recent studies conducted in a mouse skin 6 
carcinogenesis model show that weight loss induced a significant reduction of the 7 
circulating levels of IGF-1 and other hormones, including insulin and leptin, resulting in 8 
reduced IGF-1-dependent signaling pathways, i.e., Ras-MAP-proliferation and Akt-9 
PI3K-antiapoptosis. Selective targeting IGF-1 to Akt/mTOR and AMPK pathways, via 10 
negative energy balance, might inactivate cell cycle progression and ultimately 11 
suppress tumor development. This review highlights the current studies focused on the 12 
major role of reducing IGF-1-activated signaling via weight control as a potential cancer 13 
preventive mechanism.  14 
Keywords: weight control, dietary calorie restriction, exercise, cancer prevention, IGF-1 15 
signaling 16 
Short Title: IGF-1 Pathways and Cancer Prevention 17 
 18 
Introduction 19 
Maintaining a healthy body weight emerges as a strategy to generally reduce cancers 20 
and has also been suggested to reduce cancer risk. With the increasing prevalence of 21 
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obesity in both adults and children, it is important to identify the mechanism underlying 1 
cancer prevention via weight control. Current studies have focused on how 2 
understanding the molecular mechanisms of weight control, via dietary calorie 3 
restriction (DCR) and/or physical exercise, in both mouse model and human studies, 4 
prevent cancer. These studies will lead to future chemoprevention strategies for cancer. 5 
Overweight/obesity as a risk factor of cancer 6 
It is well known that obesity has a substantial influence on the development of many 7 
chronic diseases, including cancer. Numerous prospective and case-control studies that 8 
address the effect of body weight on cancer risk, estimate that excess body weight and 9 
sedentary life style account for about 39% of endometrial, 25% of kidney, 11% of colon, 10 
9% of postmenopausal breast cancer, and 5% of total cancer incidence.1 The 11 
prevalence of obesity in the U.S. rose to approximately 25% and is projected to 12 
increase to more than 40% by 2030. In children and adolescents between the ages of 6 13 
and 17 years, the prevalence of obesity appears to be increasing even more rapidly 14 
than in adults in industrialized and developing countries.2 It has been suggested that 15 
those who are 25% over normal weight have a 33% greater cancer risk than those who 16 
maintain an ideal body weight.3 Therefore, weight control to prevent obesity has been 17 
recommended as a strategy for reducing cancer risk by the American Cancer Society 18 
(ACS) as early as 1996. 19 
In obese patients and animals, insulin/leptin resistance, inflammation, and 20 
changes in hormone and growth factor concentrations are found to be key pathogenic 21 
factors that lead to many types of cancer, including breast, colon, pancreas, and 22 
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endometrium. These hormones, or growth factors, include insulin, leptin, and Insulin 1 
growth factor-1(IGF-1). They directly or indirectly provide a mitogenic effect in many cell 2 
types, especially in pre-neoplastic cells, by inducing proliferative and anti-apoptotic 3 
mechanisms.4-6 In vitro studies demonstrate that insulin, through binding to the insulin 4 
receptor, increases neoplastic proliferation at both physiological and pharmacological 5 
doses.7-9 Recently, hyperinsulinemia associated with the IGF-1 signaling pathway has 6 
been widely studied, and the condition strongly stimulates the development and growth 7 
of several tumors, especially in breast cancer.10-12 Hyperinsulinemia is associated with 8 
increased circulating free sex hormones, such as estrogen and androgen, via inhibiting 9 
the hepatic production of sex hormone-binding globulin.13  Altered adipokine production 10 
is also associated with insulin resistance. Adiponectin, one of the most abundant 11 
adipokines, is shown to be both anti-angiogenic and anti-inflammatory, and is lower in 12 
circulation in both obese and cancer patients.14-18  13 
A high level of serum leptin in obese patients has been associated with increased 14 
cellular proliferation and angiogenesis across a wide variety of cancer subtypes, 15 
including colon, prostate and breast cancer.19-25 The role of leptin in vascular 16 
remodeling may be independent of or coupled with vascular endothelial growth factor 17 
(VEGF) and fibroblast growth factor (FGF).26 Additionally, leptin stimulates several types 18 
of pre-neoplastic and neoplastic cells by mediating IGF-1R, resulting proliferation27-29 19 
and/or anti-apoptosis.30-32  20 
Levels of proinflammatory cytokines, including IL-6, TNF- and IL-1are found 21 
to be higher in obese mice and humans.  Adipose tissue is a major source for these 22 
cytokines, contributing up to 35% of circulating IL-6.33 Levels of these cytokines are also 23 
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elevated in cancer patients.34,35  Although it is still unclear how these cytokines play a 1 
combined role in tumorigenesis, activation of NF-B and STAT3 seem to be likely 2 
associated.36-41     3 
Weight control via DCR inhibits tumor development in rodents 4 
DCR is the most efficient method of weight control. The first work to show that incidence 5 
of tumors in mice positively correlated with food intake was published in 1944 by Tui 6 
and colleagues.42 To date, DCR has been the most widely studied and most potent, 7 
broadly acting dietary intervention for cancer prevention in various experimental 8 
models.43,44 DCR is a dietary regimen that restricts calorie intake without malnutrition 9 
(usually by 20%–40% relative to ad libitum-fed controls from lipids and carbohydrates, 10 
but same amount of proteins, micronutrients and minerals, etc.). DCR-fed wildtype 11 
animals are typically healthier, live longer, and more active than their ad libitum-fed 12 
counterparts45.  13 
DCR inhibits various spontaneous tumor developments in experimental animals. 14 
In rodents, a 20-40% below the usual ad libitum intake initiated early in life led to 15 
approximately 20-60% reduction in tumor incidence, including tumors of mammary, liver, 16 
colon, skin, pancreas, bladder, and leukemia.46,47 In p53-deficient mice, both juvenile- 17 
and adult-initiated calorie restriction to 60% of ad libitum intake, significantly delayed 18 
tumor development.48,49 In ApcMin mice, calorie intake restricted by 40% of the ad 19 
libitum-fed mice reduced intestinal polyps by 57%.49,50 DCR is also well documented to 20 
suppress carcinogen-induced carcinogenesis, like benzo()pyrene51 and 7,12-21 
dimethylbenz()anthracene (DMBA)52.    22 
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Weight control via exercise 1 
Epidemiological studies report that physical activity can reduce the risk of many types of 2 
cancers, especially cancer of the prostate, breast, endometrial, and lung.53 Evidence 3 
suggests that 4–7 hours per week of moderate to vigorous physical activity is required 4 
for adequate risk reduction.53 However, in the U.S., adults are not achieving the 5 
recommended amounts of physical activity, according to ACS guidelines.54-59 6 
Despite the large numbers of studies conducted, cancer prevention by physical 7 
activity in animal models is not consistent. This is largely due to the lack of precise 8 
quantitative characteristics of duration and intensity of exercise as well as the control of 9 
the dietary calorie intake. Therefore, the impact of exercise on cancer development 10 
should be considered in combination with an isocaloric diet.  11 
Decreased IGF-1 signaling in cancer prevention 12 
There are several hypotheses describing mechanisms by which weight control via DCR 13 
and/or exercise may reduce tumor development. Some hypotheses include decreased 14 
oncogene expression, improved DNA repair, enhanced scavenging of reactive oxygen 15 
species, and altered levels of cancer-related hormones.60  16 
Hormone alteration seems to be a critical factor for cancer prevention by weight 17 
control, due to the significant role of hormones in regulating cellular growth. Previous 18 
researchers have found that the levels of IGF-162-64, insulin61, and leptin61,65-67 19 
decreased significantly in rodents in response to DCR.  20 
Page  7 
 
IGF-1 is a major endocrine and paracrine regulator of cellular growth and 1 
metabolism. Binding of IGF-1 to IGF-1R activates many signaling pathways, including 2 
Jun N-terminal Kinases (JNK), p38 MAPK and PI3K via activation of receptor tyrosine 3 
kinases and/or the Ras proto-oncogene, to mediate suppression of apoptosis and 4 
contribute proliferation and cell growth.74-78 IGF-1R is overexpressed in many 5 
tumors.70,71 Abundant epidemiologic evidence supports the hypothesis that IGF-1 is 6 
involved in several types of human cancers.68,69 Adult HK1.IGF-1 mice that 7 
overexpressed IGF-1 spontaneously developed papillomas faster than non-transgenic 8 
littermates.72,73  Adult HK1.IGF-1 mice showed enhanced signaling through the 9 
Akt/mTOR pathways79, which suggested a critical role of IGF-1 in activating Akt/mTOR 10 
pathway that regulates cell proliferation, survival and energy metabolism. Activated 11 
mTOR signaling through the Akt/mTOR pathway in Akt overexpressing mouse caused 12 
alterations in epidermal proliferation and differentiation.79 The mice are more sensitive 13 
to topical 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment. Activation of IGF-1R 14 
also indirectly acts with other cancer-related molecules, such as p53, known to arrest 15 
cell growth and induce apoptosis with increased levels of p21 and reduced Bcl-2.80 16 
Reduction in glucose and insulin levels, as well as IGF-1, has been well 17 
documented in DCR-fed mice from different labs. Levels of circulating IGF-1 are 18 
influenced by dietary energy intake, which may be due to changing growth hormone-19 
regulated hepatic synthesis of IGF-1.81 Restoration of IGF-1 in p53-deficient mice 20 
reversed DCR-induced cancer protection, suggesting a requirement of reduced levels of 21 
IGF-I.16 While 20% DCR-fed SENCAR mice showed a significant reduction of plasma 22 
IGF-1 levels, a remarkable decrease of IGF-1-dependent Ras/MAPK and PI3K/Akt 23 
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signaling was demonstrated in TPA-stimulated skin tissues.82,83  Both down-expression 1 
of PCNA as a biomarker of proliferation and up-expression of Caspase-3 as a 2 
biomarker of apoptosis were also subsequently found in those mice.82,83 3 
Diet-induced changes in Akt/mTOR signaling have been reported in various 4 
organ tissues (i.e., liver, skin epidermis, and mammary fat pad). DCR-induced increase 5 
of AMP/ATP ratio may inhibit AMPK signaling that regulates mTOR activity and thereby 6 
inhibits the targeted protein production. These changes appear to be related to the 7 
reduction of circulating IGF-1 levels. In such study, 30% DCR regimen for 15-17 weeks 8 
is sufficient to lower circulating IGF-1 concentrations and inactivate Akt and mTOR 9 
signaling in multiple epithelial tissues, regardless of genetic background of the 10 
experimental mice.84 These results suggest that DCR induced a decrease of IGF-1 11 
should play a central role in response with negative energy balance-altered depression 12 
of mTOR activity.85  13 
In addition, an important study has revealed that DCR contributes to mammalian 14 
cell survival by inducing Sirtuin 1 (SIRT1) deacetylase, which deacetylates the DNA 15 
repair factor Ku70. Ku70 can prevent the proapoptotic factor Bax from mitochondrial 16 
entry, therefore inhibiting stress induced apoptosis.86 This impact is probably mediated 17 
by insulin/IGF-1 because treatment with insulin and/or IGF-1 can reduce SIRT1 18 
deacetylase expression.86 19 
In humans, 15 weeks of moderate exercise changes the levels of fasting insulin, 20 
glucose, IGF-I, IGF-II, IGFBP-1, IGFBP-3, and IGF-I:IGFBP-3 molar ratio.87,88 However, 21 
a 12-month exercise regimen did not change IGF-1 and IGFBG-3 levels in 22 
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postmenopausal women.89 Regular exercise alters the serum IGF-1 axis in vivo and 1 
reduces prostate (LNCaP) tumor cell proliferation by enhancing the function of the p53 2 
gene 90,91 In SENCAR mice, weight loss by 10-week physical activity with iso-caloric 3 
intake as sedentary controls was able to inhibit PI3K signaling and increase caspase-3 4 
activity. 82  These effects were partially reversed by IGF-1 restoration.82 Microarray 5 
analysis comparing TPA-induced gene expression profiles in DCR- or exercise-treated 6 
mouse skin tissues revealed 411 genes affected by DCR versus only 67 affected by 7 
exercise with iso-caloric intake, including PI3K and MAPK pathway genes.82-83 Similar 8 
results of  mammary gland gene expression are found in C57BL/6 mice with a 30% 9 
DCR versus exercise.92 The increased expression of fatty acid elongase-1 in treadmill 10 
exercised mice with iso-caloric intake suggests that exercise may affect the 11 
phospholipid profile.93 In addition, a lipidomics study using electrospray ionization-12 
tandem mass spectrometry demonstrated that 57 phospholipids were significantly 13 
changed among a total of 338 species detected, and 25 species were closely related to 14 
exercise by a stepwise discriminant analysis.93-94  These combined results indicate that 15 
DCR and/or exercise may target IGF-1-dependent signaling directly for a potential 16 
cancer prevention. 17 
IGF-1 signaling as a potential target for cancer prevention 18 
Effective prevention and treatment strategies are urgently needed for anti-tumorigenesis. 19 
Considering the central role that IGF-1 played on cancer development, decreasing IGF-20 
1 signaling either by chemical intervention or genetic interference has been intensively 21 
studied. Liver IGF-1-deficient (LID) mice have been utilized to mimic the effect of DCR 22 
on reducing circulating IGF-1.95 These mice had about 75% reduction in the level of 23 
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circulating IGF-1.  Repressed IGF-1R, EGFR and Akt/mTOR were observed in the skin 1 
tissue of LID mice after TPA treatment. LID mice initiated with DMBA and promoted with 2 
TPA, developed fewer and slower growing of papillomas compared with untreated 3 
littermates.95 In another study that tested if DCR effect can be replicated by 4 
chemotherapy, mice transplanted with Panc02 murine pancreatic cancer cell were 5 
treated with either DCR or rapamycin for 20 weeks.96 Rapamycin treatment (2.5 mg/kg 6 
intraperitoneal every other day) did not decrease body weight, IGF-1 or leptin level, 7 
unlike DCR, but inhibited glucose responsiveness.  Mice that received rapamycin had 8 
depressed mTOR signaling and had significantly reduced tumor volume compared to 9 
untreated mice, although to a lesser extent than DCR-fed mice. These results suggest 10 
that the downstream modulators of IGF-1 pathway can be a potential target for cancer 11 
prevention supplements. 12 
Conclusion 13 
Many epidemiological, clinical, and experimental studies have revealed a positive 14 
relationship between weight control via DCR or physical activity, and the frequency of 15 
various cancers. Reductions in the levels of circulating IGF-1 and other mitogenic 16 
hormones/growth factors, including insulin and leptin induced by DCR or physical 17 
activity, efficiently inactivate the downstream signaling pathways via IGF-1R as 18 
summarized in details in Figure 1. Future studies aimed at further elucidating the 19 
mechanisms underlying the cancer prevention possibilities of weight control may finally 20 
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Figure 1. Schematic illustration of IGF-1- and/or leptin-induced signaling pathways that 2 
may be targeted by weight control via dietary calorie restriction and exercise. 3 
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